Andrew C. Jackson - 03 Sep 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Reporting relationship: Chief Financial Officer
Issuer ticker: CLDI
Reported as of: 03 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Sep 2025, 19:56:26 UTC
Prior SEC filing: 25 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Jackson

Key filing fact

Andrew C. Jackson filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 05 Sep 2025.

Key facts

This page summarizes Andrew C. Jackson's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Sep 2025, 19:56.

Change

Previous filing in this sequence was filed on 25 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001636738 Primary reporting owner

Jackson Andrew C.

Relationship: Chief Financial Officer
Address: C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,
Signature: /s/ Andrew Jackson
Signature date: 05 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLDI transaction Derivative

Stock Options (right to buy)

Award

Transaction value
Shares: +30,000
Change %
Price
Shares after: 30,000
Date: 03 Sep 2025
Ownership: Direct
Underlying class: Common stock
Underlying amount: 30,000
Exercise price: $1.58
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on September 3, 2025 (the "Grant Date"), the Reporting Person was granted 30,000 incentive stock options (the "Options") at an exercise price of $1.58, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 9/03/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.